Drug Profile
Doxycycline - OncoSynergy
Alternative Names: NX-101; OS-342Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NexGenix Pharmaceuticals
- Class Antibacterials; Antimalarials; Antineoplastics; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neurofibromatosis 1
Most Recent Events
- 17 Jul 2007 Phase-II clinical trials in Neurofibromatosis 1 in Mexico (Topical)